Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Julia Benedetti

Dermatology Burlington, MA Medical Doctor

NPI 1912135153 CMS profile 1100943

20 Wall St, Lahey Clinic, Inc., Burlington, MA 01803

Open in the dashboard

General payments

$10,950

13 records reported · program years 2019–2025

Research payments

$723

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Julia Benedetti of Burlington, MA is reported in the CMS Open Payments database as having received $10,950 across 13 general payments and $723 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,250 1
2025 Research $723 2
2023 General $3,550 2
2022 General $1,550 2
2021 General $1,550 2
2020 General $250 1
2019 General $1,800 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Julia Benedetti
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Julia Benedetti were reported at $2,250. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Julia Benedetti Dermatology median Middle half National median
2019 $1,800 $454 $129–$1,240 $163
2020 $250 $235 $81–$756 $114
2021 $1,550 $377 $108–$1,108 $132
2022 $1,550 $514 $143–$1,391 $149
2023 $3,550 $607 $159–$1,674 $160
2024 $0 $751 $204–$1,903 $164
2025 $2,250 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $10,950 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,950 13 payments
Research payments came from Research payments · program years 2019–2025
  1. Servier Pharmaceuticals LLC $723 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

453

Median for Dermatology: 534

Drug cost

$112,807

Median for Dermatology: $67,151

Branded share of claims

24.9%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 16 $98,640
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 40 $3,664
Fluorouracil Generic 41 $2,498
Clobetasol Propionate Generic 37 $1,681
Metronidazole Generic 37 $1,478
Ketoconazole Generic 42 $850
Triamcinolone Acetonide Generic 51 $732
Betamethasone Dipropionate Generic 16 $574
Clindamycin Phosphate Generic 21 $489
Doxycycline Hyclate Generic 14 $478

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$49,700

Medicare's payments for the services billed

Medicare patients

470

Average age 77

Services billed

1,042

263 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 41%
Chronic kidney disease 22%
Cancer 22%
Ischemic heart disease 21%
Osteoporosis 20%
Diabetes 16%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record